Triglyceride deposit cardiomyovasculopathy in hemodialysis patients was associated with higher in-stent late loss after DES implantation compared to non-TGCV (median 1.17 mm vs 0.29 mm; p<0.001).
Cohort (n=26)
No
Does the presence of triglyceride deposit cardiomyovasculopathy predict higher vascular failure after drug-eluting stent implantation in hemodialysis patients?
Triglyceride deposit cardiomyovasculopathy is associated with significantly higher in-stent late loss, restenosis, and target lesion revascularization after drug-eluting stent implantation in hemodialysis patients.
Absolute Event Rate: 1.17% vs 0.29%
p-value: p=<0.001
Patients on hemodialysis (HD) are at high risk of vascular failure after percutaneous coronary intervention (PCI), even with new-generation drug-eluting stents (DES). Triglyceride deposit cardiomyovasculopathy (TGCV), a recently recognized cardiac metabolic disorder, features defective intracellular triglyceride hydrolysis with diffuse, concentric coronary narrowing, which may attenuate DES efficacy through distinct vascular remodeling biology, but its clinical impact remains unclear. This is a subanalysis of a retrospective, single-center study evaluating the prevalence and clinical outcomes of TGCV among HD patients. We included HD and catheter database data between April 2011 and March 2017. Among 118 patients suspected coronary artery disease, 26 patients who underwent 123I-β-methyl-iodophenyl-pentadecanoic acid scintigraphy and a 12-month follow-up coronary angiography after DES implantation were analyzed. Patients were divided into the TGCV or non-TGCV group. The primary endpoint was in-stent late loss. The secondary endpoints were binary in-stent restenosis (ISR) and target lesion revascularization (TLR). Nine patients (34.6%) had TGCV. In-stent late loss was higher in the TGCV group than in the non-TGCV group (median 1.17 mm versus 0.29 mm; p p = 0.005; adjusted odds ratio OR 18.1, 95% confidence interval CI 2.23-146 and 50.0% versus 9.5%; p = 0.015; adjusted OR 12.3, 95% CI 1.62-93.2, respectively). TGCV was associated with higher vascular failure after DES implantation in HD patients, and might represent a potential therapeutic target after PCI. Given the small cohort and wide CIs, these findings are preliminary and hypothesis-generating, warranting validation in larger, prospective studies.
Fujimoto et al. (2026) conducted a cohort in Hemodialysis patients with suspected coronary artery disease (n=26). Triglyceride deposit cardiomyovasculopathy (TGCV) vs. Non-TGCV was evaluated on In-stent late loss (p=<0.001). Triglyceride deposit cardiomyovasculopathy in hemodialysis patients was associated with higher in-stent late loss after DES implantation compared to non-TGCV (median 1.17 mm vs 0.29 mm; p<0.001).